Enterprise Value
233.7M
Cash
174.3M
Avg Qtr Burn
-69.37M
Short % of Float
27.33%
Insider Ownership
0.38%
Institutional Own.
65.07%
Qtr Updated
09/30/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNTEGLO (beti-cel) Details Beta thalessemia | Approved Quarterly sales | |
SKYSONA (eli-cel) (Lenti-D) Details cerebral adrenoleukodystrophy | Approved Quarterly sales | |
ABECMA (ide-cel) (bb2121) Details Multiple myeloma | Approved Quarterly sales | |
LYFGENIA (Lovo-cel) (LentiGlobin) (bb1111) Details Sickle cell disease | Approved Quarterly sales | |
Lovo-cel Details Sickle cell disease | Phase 3 Data readout |